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ABSTRACT
There is an increasing interest in exploring clinically relevant information that is present in
body fluids, and extracellular vesicles (EVs) are intrinsic components of body fluids (“liquid
biopsies”). In this report, we will focus on blood. Blood contains not only EVs but also cells,
and non-EV particles including lipoproteins. Due to the high concentration of soluble
proteins and lipoproteins, blood, plasma and serum have a high viscosity and density,
which hampers the concentration, isolation and detection of EVs. Because most if not all
studies on EVs are single-centre studies, their clinical relevance remains limited. Therefore,
there is an urgent need to improve standardization and reproducibility of EV research. As
a first step, the International Society on Extracellular Vesicles organized a biomarker work-
shop in Birmingham (UK) in November 2017, and during that workshop several working
groups were created to focus on a particular body fluid. This report is the first output of
the blood EV work group and is based on responses by work group members to
a questionnaire in order to discover the contours of a roadmap. From the answers it is
clear that most respondents are in favour of evidence-based research, education, quality
control procedures, and physical models to improve our understanding and comparison of
concentration, isolation and detection methods. Since blood is such a complex body fluid,
we assume that the outcome of the survey may also be valuable for exploring body fluids
other than blood.
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Introduction
At present, there is a growing concern about reproduci-
bility in biomedical sciences [1–4]. This holds true for the
new and exponentially growing field of extracellular vesi-
cles (EVs). To improve rigor and reproducibility, mini-
mal requirements, position papers, and guidelines have
been published by the International Society for
Extracellular Vesicles (ISEV) as well as other societies,
and platforms, for example EV-TRACK, were launched
[5–8]. Because EVs are a relatively new field of research,
we have the unique opportunity to improve the standard
of our research by learning lessons from other related
fields, which may give us a head start on addressing the
problem of reproducibility as encountered elsewhere in
biomedical sciences.
Despite these attempts, we are still facing a “Catch 22
problem” wherein we lack reliable analytics, which in turn
hampers monitoring pre-analytical variables. For example,
even today, with thousands of papers being published on
EVs annually, we are still unable to accurately measure all
EVs in any given sample. Even for flow cytometry, thus far
the most widely used method to detect single EVs, still
a 1,000-fold difference is observed in the concentration of
EVs in human plasma across different studies [9].
ISEV is working towards improvements for the stan-
dardization and reproducibility of EV research to
improve the comparability of results between instru-
ments and institutes. The blood EV work group has an
important task to improve the rigor and reproducibility
of blood collection and handling for studies on EVs,
which in turn are prerequisites to establish reliable bior-
epositories for EV biomarker research. Because blood is
a complex fluid and the most studied biofluid for EV
biomarker research, likely lessons can be learned here
and applied to other body fluids, such as urine, saliva
and cerebrospinal fluid. Besides the more general chal-
lenges there are also blood-specific challenges to which
the blood EV work group will pay attention [10–14].
During the ISEV 2018 meeting in Barcelona, Spain,
there were presentations at the inaugural blood EV work-
group by Aled Clayton (AC), Chris Gardiner (CG), An
Hendrix (AH), Kenneth Witwer (KW) and Rienk
Nieuwland (RN). Based on these presentations and the
ISEV Biomarker workshop in 2017, Birmingham, UK,
a list of variables was prepared with regard to blood collec-
tion, handling and storage (Supplementary Table 1). Then,
a brief questionnaire was sent to the kick-off team (to ask
their opinion about: (1) Inviting a limited number of (pos-
sibly non-ISEV) experts, (2) to go for evidence-based
guidelines, and (3) whether to characterize the end-
product (in addition to describing the applied methodol-
ogy), e.g. by measuring the concentration of residual
platelets. Answers were unanimously “Yes” to the three
questions. The information from this first questionnaire
was used to develop a second questionnaire (RN;
June 2018), which was sent to and filled in by 22 blood
EV work group participants, including 6 members of the
ISEV board. Two partipants joined later, and RN did not
fill in the questionnaire.
The present report summarizes the outcome of
this second questionnaire, which we hope may help
to develop a sensible, acceptable and straightforward
roadmap to improve the rigor and reproducibility of
measurements of EVs in blood. To exclude bias and
prejudice, the feedback from all participants have been
summarized as quotes in the supplementary informa-
tion because many answers contain valuable and rele-
vant information or advice. Figure 1(a) summarizes the
responses to the most pertinent questions, and high-
lights a good agreement amongst the participants. In
Figure 1(b) the outcomes of this questionnaire are used
to develop a straightforward roadmap to improve EV
measurements in blood. The results reported here have
also been used to build a survey that was launched
amongst all ISEV members before the ISEV 2019 meet-
ing in Kyoto, Japan, during which a sneak preview of
the results from this survey were shown.
Questionnaire
The questionnaire consisted of questions regarding the
background and experience in working with blood and
EVs, followed by the specific questions which will be
discussed in this report (please see Supplementary
information, Questionnaire).
Background of participants
Of the 22 participants, 20 are academic scientists and two
are clinician-scientists. Seventeen participants have ≥
5 years of experience in working with blood samples for
EV research.
Involvement of non-ISEV members
All participants (100%) were in favour of involve-
ment of non-ISEV members (Supplementary Table 2;
Figure 1(a)). To the related question “When inviting
non-EV experts (e.g. from more clinical societies), do
you think it is important to do this strategically?”,
27% of participants indicated that experts should be
selected based on experience, while 64% was in
favour of selection based on their strategic position
(Supplementary Table 3). In summary, there was
consensus that experts from outside ISEV should be
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invited when deemed necessary or helpful, and these
experts should be chosen on experience and/or their
strategic position, e.g. regarding their influence
within societies, on legislation, etc. Also the involve-
ment of working groups from other societies could
be a valuable addition.
Do we go for evidence-based guidelines?
During the ISEV Biomarker workshop, a list of variables
associated with blood collection, handling and storage was
prepared (Supplementary Table 1), and it was questioned
whether recommendations about all variables should be
evidence-based. Of the participants, 86% were in favour of
evidence-based guidelines, while 14% raised concerns
about feasibility (Supplementary Table 4, Figure 1(a)).
Taken together, most participants are in favour of evi-
dence-based guidelines, at least in part or when feasible.
As an alternative, “majority-based” or “consensus-based”
instead of “evidence-based” were suggested, but in case of
“not evidence-based” this limitation should be made clear
in manuscripts, etc.
Should we address all pre-analytics variables, or
(only) those considered to be most critical?
Of the participants, 41% was in favour of addressing all
variables, two participants (9%) suggested to address all
variables to identify the critical steps, while 50% was in
favour of identifying the most critical steps. One partici-
pant did not answer the question. In summary, 59%
support an evidence-based approach to identify the
most critical steps (Supplementary Table 5).
How to identify the critical steps?
The participants came up with three suggestions: (1)
questionnaire (45%), (2) Rand-type approach (sending
a questionnaire to experts; 20%) and (3) literature search
(15%). Of note, one participant did not answer the ques-
tion, one participant was critical about questionnaires,
one participant noticed that a questionnaire and Rand
approach are likely to give the same end-result, one
participant pointed out that a Rand-type approach may
be valuable when experts from difference fields/compe-
tence are included, and one participant suggested
(a)
(b)
Figure 1. (a) Summary of answers to the main questions by participants of the blood work group on extracellular vesicles. (b) Roadmap
towards collection, handling and storage of blood extracellular vesicles.
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“Consensus – as they are a mean to measure progress in
themselves with time and knowledge”. Taken together, in
case the critical steps must be identified, one or more
possibly combined options are recommended by partici-
pants, which include questionnaires, Rand-type
approach, and literature survey.
Do critical steps depend on the downstream
application?
In total, 17 participants (77%) agreed with this propo-
sition, and most participants provided one or more
examples, summarized in Supplementary Table 6.
Is there a role for education?
Most participants (86%) clearly considered education
important, although some noticed that it may be too early
given the lack of evidence and complexity (Figure 1(a),
Supplementary Table 7). Alternatively, some participants
thought education is useful to raise awareness for standar-
dization and reproducibility. Finally, some participants
suggested the involvement of other societies and/or work-
ing groups. Some participants pointed out that education
must be based on facts, and several suggestions were made
as to how education could be set-up.
Quality control of prepared plasma and serum?
Although pre-analytical variables can be recorded in
EV-TRACK [5], even a detailed standard operating
procedure to prepare for example plasma offers no
guarantee that the prepared samples are comparable
between individuals and laboratories. Therefore, the
participants were asked their opinion on describing
the plasma or serum in a quantitative manner. For
example, the goal of blood centrifugation protocols is
to prepare platelet-depleted plasma. Then why not
measure and quantify the residual platelet count in
the “platelet-depleted” plasma to monitor the efficacy
of the centrifugation procedure, etc.? A quantitative
description of the prepared samples provides insight
into the quality and consistency of the prepared plasma
or serum samples, and enables setting-up reliable bior-
epositories for future research on EVs. Indeed, 95% of
the participants support this approach (Figure 1(a),
Supplementary Table 8). Two participants already mea-
sure residual platelets, and one participant had
reservations.
Taken together, there is nearly consensus on
describing the end-product, in our case the EV-
containing plasma or serum, in a quantitative manner.
Which parameters are relevant and should be
measured is a matter of debate and specific training
and education may be involved, but the goal is to
improve (and check) the efficacy of described proce-
dures, and to monitor the quality and consistency of
samples prepared for experimental evaluation and
biorepositories.
Are physical models a useful instrument to improve
our understanding of procedures being used to
prepare ev-containing fluids?
Some pre-analytical steps may apply not only to blood
but also to other body fluids, e.g. centrifugation protocols.
In centrifugation models, density and viscosity of fluids
are taken into account, and such models can be used to
predict the composition of the end-product, for example
with regard to confounders such as residual platelets [15].
Obviously, physical models only have relevance when
they can be validated. In that regard, the fluorescence
and light scattering models that have been developed to
enable the comparison of fluorescence and light scatter
signals between flow cytometers are an excellent example
of attempts to compare in a quantitative manner the
fluorescence, size and concentration of EVs measured
on different instruments [16,17].
Although the majority of participants (68%) was in
favour of developing such physical models (Figure 1(a),
Supplementary Table 9), two participants were worried
about cross comparison between body fluids (but this
is actually precisely where such models may have
added value), and in total five answers were discarded
(25%): one participant indicated to lack sufficient
know-how to answer this question, three answers
gave no insight in whether they were in favour or not
for the development of physical models, and one parti-
cipant made a remark about “reference EVs”. The latter
is by itself another relevant point, but this was not
taken up in the questionnaire in its present form.
Do you think we need multiple road maps
(“highways versus byways”)? for example, easy
roadmaps for the clinical setting and more detailed
roadmaps for laboratories? or per downstream
application? other?
An overview of all answers is provided in the
Supplementary Table 10. Clearly, some participants are
in favour of multiple road maps, some in favour of multi-
ple road maps sharing commonalties, and some in favour
of a single roadmap. One participant indicated that the
downstream application affects the roadmap rather than
the difference between clinical setting and laboratories.
There were also several participants in favour of
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a “highway roadmap” for all. One participant suggested
that the “Downstream applications should dictate the
roadmap.” Two participants did not answer the question,
and one participant indicated not to understand the
question. Finally, one participant (JW) came up with an
interesting and comprehensive long-term picture and the
response is depicted fully in the supplemental table 10.
Conclusions
This report is a first step to improve the rigor and repro-
ducibility of blood EV research, and forms part of the
basis of a survey that was launched amongst ISEV mem-
bers before the ISEV meeting in Kyoto (April 2019). In
Figure 1(b) an outline is provided for a roadmap towards
collection, handling, and storage of blood needed for EV
analysis, in which measuring the sample quality prior to
the analysis of EVs, will provide direct insight into the
efficacy of the preceding blood collection and handling
protocols. Moreover, monitoring the specimen quality
and transparent reporting will improve the rigor and
ultimate reproducibility of downstream analysis. These
suggested changes provide a pragmatic and achievable
pathway to accelerate the quality of vesicle biomarker
discovery and assay design, and will inform best practice
for setting-up reliable biorepositories compatible with
vesicle-related readouts.
We hope that the outcome of this questionnaire will
steer discussions between members of ISEV and other
societies and shape further the roadmap towards repro-
ducible and credible research on blood EVs.
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